Update on viral hepatitis: 2006

Current Opinion in Gastroenterology

Volumn 23, Issue 3, 2007, Pages 263-267

  Tan, Jessica ^a   Lok, Anna S F ^a  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

Antiviral resistance; Hepatitis B; Hepatitis C; Hepatitis D; Pegylated interferon

Indexed keywords

ADEFOVIR; ENTECAVIR; ERYTHROPOIETIN; INTERFERON; LAMIVUDINE; NUCLEOSIDE DERIVATIVE; PEGINTERFERON; PEGINTERFERON ALPHA2B; RIBAVIRIN; TENOFOVIR; VIRUS DNA;

ADD ON THERAPY; AFRICAN AMERICAN; CLINICAL TRIAL; DELTA AGENT HEPATITIS; DRUG DOSE TITRATION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; GENOTYPE; HEMODIALYSIS PATIENT; HEPATITIS A; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS E; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LOADING DRUG DOSE; MULTIDRUG RESISTANCE; PATIENT COMPLIANCE; PREDICTION; REVIEW; RISK ASSESSMENT; TREATMENT DURATION; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; VIRUS HEPATITIS;

ANTIVIRAL AGENTS; DNA, VIRAL; HEPATITIS VIRUSES; HEPATITIS, VIRAL, HUMAN; HUMANS; MORBIDITY; PROGNOSIS; WORLD HEALTH;

EID: 34147144705     PISSN: 02671379     EISSN: None     Source Type: Journal    
DOI: 10.1097/MOG.0b013e328049ddc1     Document Type: Review

References (30)

1. Elinav E, Ben Dov IZ, Shapira Y, et al. Acute hepatitis A infection in pregnancy is associated with high rates of gestational complications and preterm labor. Gastroenterology 2006; 130:1129-1134.
2. Fiore AE, Wasley A, Bell BP. Prevention of hepatitis A through active or passive immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2006; 55:1-23. •This provides updated recommendations for nationwide hepatitis A vaccination.
3. Iloeje UH, Yang HI, Su J, et al. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology 2006; 130:678-686. ••This describes a very large population-based study from Taiwan showing the risk of cirrhosis in relation to HBV DNA levels. It is important to note that HBV DNA levels were measured only once, at enrolment, and that most subjects had been infected for more than 40 years at the time of enrolment.
4. Chen CJ, Yang HI, Su J, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006; 295:65-73. ••This provides a different analysis of the same study above, which shows that elevated HBV DNA levels are a risk factor for HCC.
5. Chang TT, Gish RG, de Man R, et al. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med 2006; 354:1001-1010. ••This phase III trial in HBeAg positive chronic hepatitis B showed that entecavir is more potent than lamivudine, with less resistance and equal safety profile.
6. Lai CL, Shouval D, Lok AS, et al. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2006; 354:1011-1020. ••A phase III trial in HBeAg negative chronic hepatitis B showed that entecavir is more potent than lamivudine, with equal safety profile, but better resistance profile.
7. Sherman M, Yurdaydin C, Sollano J, et al. Entecavir for treatment of lamivudine-refractory, HBeAg-positive chronic hepatitis B. Gastroenterology 2006; 130:2039-2049. ••This important study showed that though entecavir at a higher dose is more potent than continuing lamivudine in the presence of lamivudine-resistant HBV infection, virologic response is suboptimal.
8. Brunelle MN, Jacquard AC, Pichoud C, et al. Susceptibility to antivirals of a human HBV strain with mutations conferring resistance to both lamivudine and adefovir. Hepatology 2005; 41:1391-1398.
9. van Bommel F, Zollner B, Sarrazin C, et al. Tenofovir for patients with lamivudine-resistant hepatitis B virus (HBV) infection and high HBV DNA level during adefovir therapy. Hepatology 2006; 44:318-325. •This retrospective study highlighted that response to adefovir is inconsistent in lamivudine resistant patients and tenofovir is more potent than adefovir in such circumstances.
10. Fung SK, Chae HB, Fontana RJ, et al. Virologic response and resistance to adefovir in patients with chronic hepatitis B. J Hepatol 2006; 44:283-290. •This study provided evidence that adefovir resistance occurs more frequently than previously reported in nucleoside-naive patients and patients with lamivudine resistance should have adefovir added to lamivudine to prevent the appearance of adefovir resistance.
11. Yeon JE, Yoo W, Hong SP, et al. Resistance to adefovir dipivoxil in lamivudine resistant chronic hepatitis B patients treated with adefovir dipivoxil. Gut 2006; 55:1488-1495.
12. Lee YS, Suh DJ, Lim YS, et al. Increased risk of adefovir resistance in patients with lamivudine-resistant chronic hepatitis B after 48 weeks of adefovir dipivoxil monotherapy. Hepatology 2006; 43:1385-1391.
13. Yim HJ, Hussain M, Liu Y, et al. Evolution of multidrug resistant hepatitis B virus during sequential therapy. Hepatology 2006; 44:703-712.
14. Jaeckel E, Cornberg M, Wedemeyer H, et al. Treatment of acute hepatitis C with interferon alfa-2b. N Engl J Med 2001; 345:1452-1457.
15. Kamal SM, Ismail A, Graham CS, et al. Pegylated interferon alpha therapy in acute hepatitis C: relation to hepatitis C virus-specific T cell response kinetics. Hepatology 2004; 39:1721-1731.
16. Kamal SM, Fouly AE, Kamel RR, et al. Peginterferon alfa-2b therapy in acute hepatitis C: impact of onset of therapy on sustained virologic response. Gastroenterology 2006; 130:632-638. ••This well-conducted randomized controlled trial provided evidence that treatment of acute hepatits C should be initiated 12 weeks after diagnosis, to allow for spontaneous clearance and at the same time avoid compromising SVR.
17. Kamal SM, Moustafa KN, Chen J, et al. Duration of peginterferon therapy in acute hepatitis C: a randomized trial. Hepatology 2006; 43:923-931. ••This randomized controlled trial gave evidence for treatment of acute hepatitis C with 12 weeks of PEG-IFN monotherapy for non1 genotype and 12-24 weeks of treatment for genotype 1.
18. Conjeevaram HS, Fried MW, Jeffers LJ, et al. Peginterferon and ribavirin treatment in African American and Caucasian American patients with hepatitis C genotype 1. Gastroenterology 2006; 131:470-477. ••A large study that showed poor response to hepatitis C treatment in African Americans, but no obvious factors can be implicated.
19. Berg T, von Wagner M, Nasser S, et al. Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin. Gastroenterology 2006; 130:1086-1097.
20. Sanchez-Tapias JM, Diago M, Escartin P, et al. Peginterferon-alfa2a plus ribavirin for 48 versus 72 weeks in patients with detectable hepatitis C virus RNA at week 4 of treatment. Gastroenterology 2006; 131:451-460.
21. Yu ML, Dai CY, Huang JF, et al. A randomised study of peginterferon and ribavirin for 16 vs 24 weeks in patients with genotype 2 chronic hepatitis C. Gut 2006; Sep 6 [Epub ahead of print]. ••This randomized study showed conclusively that patients with genotype 2 infection can be treated with a shorter duration of combination PEG-IFN and ribavirin.
22. Taliani G, Gemignani G, Ferrari C, et al. Pegylated interferon alfa-2b plus ribavirin in the retreatment of interferon-ribavirin nonresponder patients. Gastroenterology 2006; 130:1098-1106.
23. Shiffman ML, Di Bisceglie AM, Lindsay KL, et al. Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment. Gastroenterology 2004; 126:1015-1023.
24. Russo MW, Ghalib R, Sigal S, Joshi V. Randomized trial of pegylated interferon alpha-2b monotherapy in haemodialysis patients with chronic hepatitis C. Nephrol Dial Transplant 2006; 21:437-443.
25. Bruchfeld A, Lindahl K, Reichard O, et al. Pegylated interferon and ribavirin treatment for hepatitis C in haemodialysis patients. J Viral Hepat 2006; 13:316-321.
26. Niro GA, Ciancio A, Gaeta GB, et al. Pegylated interferon alpha-2b as monotherapy or in combination with ribavirin in chronic hepatitis delta. Hepatology 2006; 44:713-720. ••This study showed that PEG-IFN is effective in hepatitis D, even in prior nonresponders, and combination with ribavirin has no additional benefit.
27. Castelnau C, Le Gal F, Ripault MP, et al. Efficacy of peginterferon alpha-2b in chronic hepatitis delta: relevance of quantitative RT-PCR for follow-up. Hepatology 2006; 44:728-735. •This study showed that PEG-IFN is effective, and RT-PCR is a useful tool to monitor virological response during therapy.
28. Kasorndorkbua C, Opriessnig T, Huang FF, et al. Infectious swine hepatitis E virus is present in pig manure storage facilities on United States farms, but evidence of water contamination is lacking. Appl Environ Microbiol 2005; 71:7831-7837.
29. Sadler GJ, Mells GF, Shah NH, et al. UK acquired hepatitis E: an emerging problem? J Med Virol 2006; 78:473-475.
30. Boxall E, Herborn A, Kochethu G, et al. Transfusion-transmitted hepatitis E in a 'nonhyperendemic' country. Transfus Med 2006; 16:79-83.